Taysha Gene Therapies, Inc. (TSHA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-13

Key Insights

The reporting person, Nagendran Sukumar, exercised 19,021 stock options at $1.71 per share and subsequently sold 200,000 shares at a weighted average price of $4.46, indicating insider selling activity.
The reporting person's holdings decreased from 1,336,410 shares to 1,136,410 shares, a 15% reduction in ownership stake.
The stock option exercise and sale were made pursuant to a pre-established Rule 10b5-1 trading plan, suggesting a planned and systematic approach to the transactions.

Insider Trading Filed: 2026-01-14

Key Insights

The CEO, Sean P. Nolan, has acquired a significant number of shares, indicating his confidence in the company's future prospects.
The CEO's equity ownership has increased substantially with the acquisition of 1,008,000 restricted stock units and a stock option grant of 648,000 shares.
The CEO now holds both direct and indirect beneficial ownership of Taysha Gene Therapies' common stock, suggesting alignment between his interests and those of shareholders.

Insider Trading Filed: 2026-01-14

Key Insights

The reporting person, Nagendran Sukumar, appears to be an officer and director of Taysha Gene Therapies, Inc. (TSHA) who has engaged in significant insider trading activity, including exercising stock options and selling shares.
Sukumar exercised 111,324 stock options at $0.6989 and 88,676 stock options at $1.71, indicating he is exercising previously granted equity awards.
Sukumar also received a grant of 427,000 restricted stock units (RSUs) with a January 2027 vesting start date, suggesting he is being compensated with additional equity.

Insider Trading Filed: 2026-01-14

Key Insights

Kamran Alam, the Chief Financial Officer of Taysha Gene Therapies, Inc., has been granted 231,000 stock options and 359,000 restricted stock units (RSUs), indicating the company's commitment to incentivizing and retaining key management.
The vesting schedule for the options and RSUs, with 25% vesting in the first year and the remainder vesting over 36 months, suggests a long-term focus on Alam's part and the company's desire to align his interests with those of shareholders.
The significant amount of equity compensation awarded to Alam, representing a significant increase in his beneficial ownership, signals the board's confidence in his leadership and the company's future prospects.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.